These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25778940)

  • 1. A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach.
    Dörre K; Olczak M; Wada Y; Sosicka P; Grüneberg M; Reunert J; Kurlemann G; Fiedler B; Biskup S; Hörtnagel K; Rust S; Marquardt T
    J Inherit Metab Dis; 2015 Sep; 38(5):931-40. PubMed ID: 25778940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mosaicism of the UDP-Galactose transporter SLC35A2 in a female causing a congenital disorder of glycosylation: a case report.
    Westenfield K; Sarafoglou K; Speltz LC; Pierpont EI; Steyermark J; Nascene D; Bower M; Pierpont ME
    BMC Med Genet; 2018 Jun; 19(1):100. PubMed ID: 29907092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients.
    Vals MA; Ashikov A; Ilves P; Loorits D; Zeng Q; Barone R; Huijben K; Sykut-Cegielska J; Diogo L; Elias AF; Greenwood RS; Grunewald S; van Hasselt PM; van de Kamp JM; Mancini G; Okninska A; Pajusalu S; Rudd PM; Rustad CF; Salvarinova R; de Vries BBA; Wolf NI; ; Ng BG; Freeze HH; Lefeber DJ; Õunap K
    J Inherit Metab Dis; 2019 May; 42(3):553-564. PubMed ID: 30746764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals.
    Ng BG; Sosicka P; Agadi S; Almannai M; Bacino CA; Barone R; Botto LD; Burton JE; Carlston C; Chung BH; Cohen JS; Coman D; Dipple KM; Dorrani N; Dobyns WB; Elias AF; Epstein L; Gahl WA; Garozzo D; Hammer TB; Haven J; Héron D; Herzog M; Hoganson GE; Hunter JM; Jain M; Juusola J; Lakhani S; Lee H; Lee J; Lewis K; Longo N; Lourenço CM; Mak CCY; McKnight D; Mendelsohn BA; Mignot C; Mirzaa G; Mitchell W; Muhle H; Nelson SF; Olczak M; Palmer CGS; Partikian A; Patterson MC; Pierson TM; Quinonez SC; Regan BM; Ross ME; Guillen Sacoto MJ; Scaglia F; Scheffer IE; Segal D; Singhal NS; Striano P; Sturiale L; Symonds JD; Tang S; Vilain E; Willis M; Wolfe LA; Yang H; Yano S; Powis Z; Suchy SF; Rosenfeld JA; Edmondson AC; Grunewald S; Freeze HH
    Hum Mutat; 2019 Jul; 40(7):908-925. PubMed ID: 30817854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short N-terminal region of UDP-galactose transporter (SLC35A2) is crucial for galactosylation of N-glycans.
    Sosicka P; Jakimowicz P; Olczak T; Olczak M
    Biochem Biophys Res Commun; 2014 Nov; 454(4):486-92. PubMed ID: 25451267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy.
    Kodera H; Nakamura K; Osaka H; Maegaki Y; Haginoya K; Mizumoto S; Kato M; Okamoto N; Iai M; Kondo Y; Nishiyama K; Tsurusaki Y; Nakashima M; Miyake N; Hayasaka K; Sugahara K; Yuasa I; Wada Y; Matsumoto N; Saitsu H
    Hum Mutat; 2013 Dec; 34(12):1708-14. PubMed ID: 24115232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy.
    Kimizu T; Takahashi Y; Oboshi T; Horino A; Koike T; Yoshitomi S; Mori T; Yamaguchi T; Ikeda H; Okamoto N; Nakashima M; Saitsu H; Kato M; Matsumoto N; Imai K
    Brain Dev; 2017 Mar; 39(3):256-260. PubMed ID: 27743886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of involvement of UGT1 and UGT2 splice variants of UDP-galactose transporter in glycosylation of macromolecules in MDCK and CHO cell lines.
    Maszczak-Seneczko D; Olczak T; Wunderlich L; Olczak M
    Glycoconj J; 2011 Oct; 28(7):481-92. PubMed ID: 21894462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLC35A2-related congenital disorder of glycosylation: Defining the phenotype.
    Yates TM; Suri M; Desurkar A; Lesca G; Wallgren-Pettersson C; Hammer TB; Raghavan A; Poulat AL; Møller RS; Thuresson AC; Balasubramanian M
    Eur J Paediatr Neurol; 2018 Nov; 22(6):1095-1102. PubMed ID: 30194038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of de novo splice site variant in SLC35A2 showing developmental delays, spastic paraplegia, and delayed myelination.
    Miyamoto S; Nakashima M; Ohashi T; Hiraide T; Kurosawa K; Yamamoto T; Takanashi J; Osaka H; Inoue K; Miyazaki T; Wada Y; Okamoto N; Saitsu H
    Mol Genet Genomic Med; 2019 Aug; 7(8):e814. PubMed ID: 31231989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation.
    Ng BG; Buckingham KJ; Raymond K; Kircher M; Turner EH; He M; Smith JD; Eroshkin A; Szybowska M; Losfeld ME; Chong JX; Kozenko M; Li C; Patterson MC; Gilbert RD; Nickerson DA; Shendure J; Bamshad MJ; ; Freeze HH
    Am J Hum Genet; 2013 Apr; 92(4):632-6. PubMed ID: 23561849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG.
    Witters P; Tahata S; Barone R; Õunap K; Salvarinova R; Grønborg S; Hoganson G; Scaglia F; Lewis AM; Mori M; Sykut-Cegielska J; Edmondson A; He M; Morava E
    Genet Med; 2020 Jun; 22(6):1102-1107. PubMed ID: 32103184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLC35A2 Deficiency Promotes an Epithelial-to-Mesenchymal Transition-like Phenotype in Madin-Darby Canine Kidney Cells.
    Kot M; Mazurkiewicz E; Wiktor M; Wiertelak W; Mazur AJ; Rahalevich A; Olczak M; Maszczak-Seneczko D
    Cells; 2022 Jul; 11(15):. PubMed ID: 35892570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of UDP-GlcNAc transporter partially corrects galactosylation defect caused by UDP-Gal transporter mutation.
    Maszczak-Seneczko D; Olczak T; Jakimowicz P; Olczak M
    FEBS Lett; 2011 Oct; 585(19):3090-4. PubMed ID: 21889501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLC35A2-CDG: novel variants with two ends of the spectrum.
    Kasapkara ÇS; Ceylan AC; Özyürek H; Karakaya Molla G; Civelek Ürey B; Kıreker Köylü O; Küçükçongar Yavaş A; Sönmez FM
    J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1185-1189. PubMed ID: 34161696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics of SLC35A2 gene variants related congenital disorders of glycosylation typeⅡ].
    Lang CH; Yang Y; Niu XY; Yang XL; Chen Y; Zhang YH
    Zhonghua Er Ke Za Zhi; 2020 Jul; 58(7):586-590. PubMed ID: 32605344
    [No Abstract]   [Full Text] [Related]  

  • 17. Galactose Supplementation in Patients With TMEM165-CDG Rescues the Glycosylation Defects.
    Morelle W; Potelle S; Witters P; Wong S; Climer L; Lupashin V; Matthijs G; Gadomski T; Jaeken J; Cassiman D; Morava E; Foulquier F
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1375-1386. PubMed ID: 28323990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a mutation and an alternative splicing of UDP-galactose transporter in MDCK-RCAr cell line.
    Olczak M; Guillen E
    Biochim Biophys Acta; 2006 Jan; 1763(1):82-92. PubMed ID: 16434112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UDP-Gal/UDP-GlcNAc chimeric transporter complements mutation defect in mammalian cells deficient in UDP-Gal transporter.
    Olczak M; Maszczak-Seneczko D; Sosicka P; Jakimowicz P; Olczak T
    Biochem Biophys Res Commun; 2013 May; 434(3):473-8. PubMed ID: 23583405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point mutations identified in Lec8 Chinese hamster ovary glycosylation mutants that inactivate both the UDP-galactose and CMP-sialic acid transporters.
    Oelmann S; Stanley P; Gerardy-Schahn R
    J Biol Chem; 2001 Jul; 276(28):26291-300. PubMed ID: 11319223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.